Aegerion revives $86M IPO; MannKind prepares to raise cash;

 @FierceBiotech: Report: China readies $1.5B plan to bolster biotech. Article | Follow @FierceBiotech

 @JohnCFierce: SciClone says the feds are probing China activities; shares plunge 32 percent. News | Follow @JohnCFierce

> Aegerion Pharmaceuticals has dusted off its old IPO plans. The developer has re-registered its $86.3 million offering, which it pulled after the 2008 market collapse. Aegerion is developing a new therapy, now in a late-stage trial, for a rare genetic disorder. Report

> MannKind plans to sell 36.4 million shares to help pay down debt. The developer is waiting for the FDA's decision on its inhaled insulin therapy Afrezza. Story

> With revenue from its China ops surging at a fast pace, Qiagen-which markets sample and assay technologies for biomarker development--says it's on track to see its Asian market cash flow double this year, according to a report from Seeking Alpha. And a recently formed partnership on molecular biomarkers with WuXi PharmaTech should help feed its swelling revenue stream. Report

> Trigemina says that a small Phase IIa trial of TI-001 produced positive results as a treatment for chronic daily headache. Trigemina release

> Researchers in Belgium have found another potential biomarker for detecting Alzheimer's. Using a spinal tap test, a team at Ghent University took samples of cerebrospinal fluid from 400 elderly individuals in varying states of dementia, and of the 102 participants considered to have Alzheimer's, 90 had an identical biomarker. Article

And Finally... UK health officials say they're alarmed to see evidence of a new superbug that is resistant to almost all existing antibiotics. News

Suggested Articles

Paragon Biosciences has hired Kerensa Jimenez as the new CEO of its capital markets group Paragon Health Capital.

Regeneron has taken a step closer to getting a green light for its experimental high cholesterol drug as the FDA allows a swift review of evicanumab.

An analysis of Gilead’s remdesivir clinical trials found the studies “failed to provide equal representation of Black, Latinx and Native Americas."